Sheet	1	of	1

				ATTY, DOCKET NO.				
OIP				P-4901		09/606,909	3	
917	eyst c	OF REFERENCES CITE	ED BY APPLICANT	APPLICANT				
· ·	5	(Use several sheets if r	necessary)	Petits, Ronald et al.				
^{LT} 2 8 200	2 (2)			FILING DATE		GROUP		
	/بري -			June 29, 2000		3748		
BADEMORY	<u> </u>		U.S. PATENT	DOCUMENTS				
*EXAMINER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING	G DATE
INITIAL				······································		<u> </u>	IF APPR	ROPRIATE
	ļ					ļ		
				ì		l	1	
		1			I	<u> </u>	<u> </u>	
	Τ.	1	FOREIGN PATE	IT DOCUMENTS		T		
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS	SLATION
	 -		 				YES	NO
						ļ	<u> </u>	
:								
		<u> </u>			L	L	L	
		OTHER RE	FERENCES (Including Au	hor, Title, Date, Pertinent Page	es, Etc.)			
						Ot 1: 1	II Anir	
R5		Bronaugh RL, Stewart	RF, Congdon ER. Met	nods for in Vitro Percutane	eous Absorption	Studies.	II. AIIII	mal
BT	AA	1	-	hods for in Vitro Percutane Pharmacol. 1982 Mar 15;6	•	i Studies. I	II. AIIII	mal
B5	AA	Models for Human Ski	in. Toxicol and Applied	Pharmacol. 1982 Mar 15;6	62(3):481-8.			
B5 B5	AA AB	Models for Human Ski	in. Toxicol and Applied on YW. Transdermal Co		62(3):481-8.			
1857 1857		Models for Human Ski	in. Toxicol and Applied on YW. Transdermal Co	Pharmacol. 1982 Mar 15;6	62(3):481-8.			
BT BT		Models for Human Ski	in. Toxicol and Applied on YW. Transdermal Co	Pharmacol. 1982 Mar 15;6	62(3):481-8.			
B T B T		Models for Human Ski	in. Toxicol and Applied on YW. Transdermal Co	Pharmacol. 1982 Mar 15;6	62(3):481-8.			
B 5		Models for Human Ski	in. Toxicol and Applied on YW. Transdermal Co	Pharmacol. 1982 Mar 15;6	62(3):481-8.			
BT BT		Models for Human Ski	in. Toxicol and Applied on YW. Transdermal Co	Pharmacol. 1982 Mar 15;6	62(3):481-8.			
B 5		Models for Human Ski	in. Toxicol and Applied on YW. Transdermal Co	Pharmacol. 1982 Mar 15;6	62(3):481-8.			
BT BT		Models for Human Ski	in. Toxicol and Applied on YW. Transdermal Co	Pharmacol. 1982 Mar 15;6	62(3):481-8. anolol from a Mu			
BT 85		Models for Human Ski	in. Toxicol and Applied on YW. Transdermal Co	Pharmacol. 1982 Mar 15;6 ntrolled Delivery of Propra	62(3):481-8. anolol from a Mu	ultilaminate		
B 5		Models for Human Ski	in. Toxicol and Applied on YW. Transdermal Co	Pharmacol. 1982 Mar 15;6 ntrolled Delivery of Propra	62(3):481-8. anolol from a Mu	ultilaminate		
BT 185		Models for Human Ski	in. Toxicol and Applied on YW. Transdermal Co	Pharmacol. 1982 Mar 15;6 ntrolled Delivery of Propra	62(3):481-8. anolol from a Mu	ultilaminate		
BT 185		Models for Human Ski	in. Toxicol and Applied on YW. Transdermal Co	Pharmacol. 1982 Mar 15;6 ntrolled Delivery of Propra	62(3):481-8. anolol from a Mu	ultilaminate		
BT 185		Models for Human Ski	in. Toxicol and Applied on YW. Transdermal Co	Pharmacol. 1982 Mar 15;6 ntrolled Delivery of Propra	62(3):481-8. anolol from a Mu	ultilaminate		
B5 B5		Models for Human Ski	in. Toxicol and Applied on YW. Transdermal Co	Pharmacol. 1982 Mar 15;6 ntrolled Delivery of Propra	62(3):481-8. anolol from a Mu	ultilaminate		
BT		Models for Human Ski	in. Toxicol and Applied on YW. Transdermal Co	Pharmacol. 1982 Mar 15;6 ntrolled Delivery of Propra	62(3):481-8. anolol from a Mu	ultilaminate		
85 85		Models for Human Ski	in. Toxicol and Applied on YW. Transdermal Co	Pharmacol. 1982 Mar 15;6 ntrolled Delivery of Propra	62(3):481-8. anolol from a Mu	ultilaminate		
B5 B5		Models for Human Ski	in. Toxicol and Applied on YW. Transdermal Co	Pharmacol. 1982 Mar 15;6 ntrolled Delivery of Propra	62(3):481-8. anolol from a Mu	ultilaminate		
85 85		Models for Human Ski	in. Toxicol and Applied on YW. Transdermal Co	Pharmacol. 1982 Mar 15;6 ntrolled Delivery of Propra	62(3):481-8. anolol from a Mu	ultilaminate		
B 5		Models for Human Ski	in. Toxicol and Applied on YW. Transdermal Co	Pharmacol. 1982 Mar 15;6 ntrolled Delivery of Propra	62(3):481-8. anolol from a Mu	ultilaminate		
85 85		Models for Human Ski	in. Toxicol and Applied on YW. Transdermal Co	Pharmacol. 1982 Mar 15;6 ntrolled Delivery of Propra	62(3):481-8. anolol from a Mu	ultilaminate		
BT		Models for Human Ski	in. Toxicol and Applied on YW. Transdermal Co	Pharmacol. 1982 Mar 15;6 ntrolled Delivery of Propra	62(3):481-8. anolol from a Mu	ultilaminate		
BST	AB	Models for Human Ski	in. Toxicol and Applied en YW. Transdermal Co 989 Sep;6(9):753-8.	Pharmacol. 1982 Mar 15;6 ntrolled Delivery of Propra	62(3):481-8. anolol from a Mu	ultilaminate		



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

bstitute for form 1449A/PTO

NOV 1 2 2002

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complete if Known					
Application Number	09/606,909				
Filing Date	June 29, 2000				
First Named Inventor	PETTIS et al.				
Group Art Unit	3748				
Examiner Name	Binh Q. TRAN				
Attorney Docket Number	P-4901				

				U.S. PATENT DOCUM	MENTS		
Examiner Cite No.1		U.S. Patent Document Kind Code ² (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Releva Passages or Relevant Figures Appear	
	AA	2,619,962		Rosenthal	12/02/1952		
	AB	3,814,097		Ganderton et al.	06/04/1974		
,	AC	3,964,482		Gerstel et al.	06/22/1976		
	AD	4,270,537		Romaine	06/02/1981		
	AE	4,592,753		Panoz	06/03/1986		
	AF	5,003,987		Grinwald	04/02/1991		
	AG	5,098,389		Cappucci	03/24/1992		
· · <u>-</u> ·	AH	5,156,591		Gross et al.	10/20/1992		
	AI	5,250,023		Lee et al.	10/05/1993		
	AJ	5,279,544		Gross et al.	01/18/1994		
	AK	5,417,662		Hjertman et al.	05/23/1995	iti cope	
	AL	5,527,288		Gross et al.	06/18/1996	오 쓰	
	AM	5,591,139		Lin et al.	01/07/1997	4 Z III	
	AN	5,801,057		Smart et al.	09/01/1998	5 2 7	
	AO	5,820,622		Gross et al.	10/13/1998	9 4	
	AP	5,848,991		Gross et al.	12/15/1998	C : 111	
	AQ	5,876,582		Frazier	03/02/1999	[1]	
	AR	5,879,326		Godshall et al.	03/09/1999	NIER ROOM	
	AS	5,928,207		Pisano et al.	07/27/1999		
	AT	5,957,895		Sage et al.	09/28/1999	3 0	
	AU	5,997,501		Gross et al.	12/07/1999	8	
	AV	6,099,504		Gross et al.	08/08/2000		
	AW	6,334,856	Bl	Allen et al.	01/01/2002		
	AX	6,346,095	BI	Gross et al.	02/12/2002		

				FOREIG	N PATENT DOCU	MENTS		
Examiner	Cite	For	eign Patent Do	cument	Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Office ³	Number⁴	Kind Code ⁵ (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ₈
	AY	CA	2 349 431		Canada	05/25/2000		
	AZ	EP	1 086 718	Al	Europe	03/28/2001		
	BA	EP	1 086 719	Al	Ешгоре	03/28/2001		
	BB	EP	1 088 642	Al	Europe	04/04/2001		
	BC	EP	1 092 444	Al	Ешгоре	04/18/2001		
	BD	wo	96/17648		PCT	06/13/1996		
	BE	wo	96/37155		PCT	11/28/1996		
<u>-</u>	BF	wo	96/37256		PCT	11/28/1996		
	BG	wo	99/43350		PCT	09/02/1999		
	BH	wo	99/64580		PCT	12/16/1999		
	BI	wo	00/67647		PCT	11/16/2000		
	BJ	wo	00/74763	A2	PCT	12/14/2000		
	BK	wo	02/11669	A2	PCT	02/14/2002		

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 09/606,909

Filing Date June 29, 2000

First Named Inventor PETTIS et al.

Group Art Unit 3748

Examiner Name Binh Q. TRAN

Attorney Docket Number P-4901

Complete if Known

(use as many sheets as necessary)

	•		•			
Sheet		2		of	2	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ2
	BL	E. AUTRET et al., Therapie 1991, 46 : 5-8.	
	ВМ	BRESSOLLE et al., "A Weibull Distribution Model for Intradermal Administration of Ceftazidime", Journal of Pharmaceutical Sciences, Vol. 82, No. 11, November 1993, pps. 1175-1178.	
	BN	HENRY et al., "Microfabricated Microneedles: A Novel Approach to Transdermal Drug Delivery", Journal of Pharmaceutical Sciences, Vol. 87, No. 8, August 1998, pps. 922-925.	
	во	KAUSHIK et al., "Transdermal Protein Delivery Using Microfabricated Microneedles", Oct/Nov 1999 (1 page).	
	ВР	BURKOTH et al., "Transdermal and Transmucosal Powered Drug Delivery", Critical Review™ in Therapeutic Drug Carrier Systems, 16 (4), (1999), pps. 331-384.	
	BQ	MCALLISTER et al., "Three-Dimensional Hollow Microneedle and Microtube Arrays", Conference: Solid-State Sensors and Actuators Transducers-Conference, 1999; 10 th ; Vol. 12, pp 1098-1103.	
	BR.	MCALLISTER et al., "Solid and Hollow Microneedles for Transdermal Protein Delivery", Proceed. Int'l. Symp. Control. Rel. Bioact. Mater., 26 (Revised July 1999) Controlled Release Society, Inc. pp. 192-193	
	BS	SEBASTIEN et al., "Microfabricated Needles: A Novel Approach to Transdermal Drug Delivery", Journal of Pharmaceutical Sciences, Vol. 87, No. 8, August 1998, pp. 922-925	
		RECEIVED NOV 1 3 2002	
		NOV 1 3 2002	
		TECHNOLOGY GENTLER R3700	
	<u> </u>	TECHNOLOGY CENTER 92700	L

Examiner /Phillip Gray/ Signature	Date 2/5/2013 Considered
-----------------------------------	--------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

	<u> </u>	PTO/SB/08A	(10-01
Approi	r use through	10/31/2002, OMB 06	351-003
J.S. Patent and Tradema	office: U.S. DE	PARTMENT OF COM	MERCI

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known						
Application Number	09/606,909					
Filing Date	June 29, 2000					
First Named Inventor	Pettis, et al.					
Art Unit	3748					
Examiner Name	Binh Q. Tran					
Attorney Docket Number	P-4901					

			U.S. PAT	TENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA —	US4,886,499	12/12/1989	Cirelli, et al.	
		US-		·	
		US-			
		US-	[

				FOR	EIGN PATENT DO	CUMENTS		
Examiner Initials*	Cite No.1			Kind⁵	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	76
855	AB	EP	0 429 842	(if known) B1	08/28/1996	Europe	Figures Appear	Ė
	AC	wo	94/23777		10/27/1994	PCT	- O = 11 /F F	
	AD	wo	97/21457		6/19/1997	PCT R	FUETVEL	ノ
8	AE	wo	00/09186		2/24/2000	PCT		
							DEC 2 3 2002	
						TECH	LOLOGY CENTER R	700
						ILUII		
					T. T. Y.	-	<u> </u>	

Examiner	$O: -\infty$	Date	21/25/2
Signature	13 INH I KAN	Considered	01/05/03

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

The reference has been cited in 2TO-892.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (option.al). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
App for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Tradenark Office: U.S. DEPARTMENT OF COMMERCE

der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

19 E 1

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
2 of 4

Complete if Known			
Application Number	09/606,909		
Filing Date	June 29, 2000		
First Named Inventor	Pettis, et al.		
Group Art Unit	3748		
Examiner Name	Binh Q. Tran		
Attorney Docket Number	P-4901		

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
BT	AF	AGRAWAL, et al., "Pharmacokinetics, Biodistribution, and Stability of Oligodeoxynucleotide Phosphorothioates in Mice", Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 7595-7599, September 1991 Medical Sciences	
	AG	AUTRET, et al., "Comparison of Pharmacokinetics and tolerance of Calcitonine administered by Intradermal or Subcutaneous Route", Fundamental Clinical Pharmacology, Vol. 3, No. 2, pp 170-171, 1989	
: 4	АН	BENONI, et al., "Distribution of Ceftazidime in Ascitic Fluid", Antimicrobial Agents and Chemotherapy, Vol. 25, No. 6, June 1984, pp. 760-763	
	ΑI	BICKERS, et al., editors, "Clinical Pharmacology of Skin Disease", pp. 57-90, Churchill Livingstone, Inc., 1984	
	ΔJ	BOCCI, et al., "The Lymphatic Route. IV. Pharmacokinetics of Human Recombinant Interferon a2 and Natural Interferon B Administered Intradermally in Rabbits", International Journal of Phamaceutics, 32, 1986, pp. 103-110 Elsevier Science Publishers B.V. (Biomedical Division)	
	AK	CALLEN, "Intralesional Corticosteriods", Journal of the American Academy of Dermatology, University of Louisville School of Medicine, pp. 149-151, 1981	
	AL	COSSUM, et al., "Disposition of the C-Labeled Phosphorothioate Oligonucleotide ISIS 2105 after Intravenous Administration to Rats", The Journal of Pharmacology and Experimental Therapeutics, pp. 1181-1190, Vol. 267, No. 3, 1993	
	AM	COSSUM, et al., "Pharmacokinetics of C-Labeled Phosphorothioate Olignucleotide, ISIS 2105 after Administration to Rats", The Journal of Pharmacology and Experimental Therapeutics, pp. 89-94, Vol 269, No. 1, 1994	
	AN	CROOKE, et al., "A Pharmacokinetic Evaluation of C-Labeled Afovirsen Sodium in Patients with Genital Warts", Clinical Pharmacology & Therapeutics, pp. 641-646, Vol. 56, No. 6, Part 1, December 1994	
	AO	FIROOZ, et al., "Benefits and Risks of Intralesional Corticosteroid Injection in the Treatment of Dermatological Diseases", pp. 363-370, Vol. 20, No. 5, Clinical and Experimental Dermatology, Blackwell Science Ltd, September 1995	
V	AP.	GOODARZI, et al., "Organ Distribution and Stability of Phosphorothioated Oligodeoxyribonucleotides in Mice, "Biopharmaceutics & Drug Disposition, pp. 221-227, Vol. 13, No. 3, John Witer & Sons, Etd., April 1992 DEC 2 3 2002	
		DEC % 3 YOUR	027
		TECHNOLOGY CENTER	91 (() ()

Examiner Signature BINH TRAN Date Considered 01/05/03

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).
² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)

Applied for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trade K Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

09/606,909

der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Filing Date June 29, 2000

First Named Inventor Pettis, et al.

Group Art Unit 3748

Examiner Name Binh Q. Tran

(use as many sheets as necessary)
Sheet 3 of 4

Attorney Docket Number P-4901

Cite Include name of the author (in CAPITAL LETTERS), tile of the article (when appropriate), tile of the item (book, magazine, journal, serial, symposium, catalog, etc.), data, page(s), volume-issue number(s), publisher, oly and/or country where published. HAYNES, et al., "Ultra-long-duration Local Anesthesis Produced by Injection of Lecithin-coated Methoxyflurane Microdroplets", Anestheiology, Vol. 63, No. 5, pp. 490-499, Nov. 1985 JAKOBSON, et al., "Variations in the Blood Concentration of I, 1,2-Trichloroethane by Percutaneous Absorption and Other Routes of Administration in the Guinea Pig", Vol. 41, No. 5, pp. 497-506, Acta Pharmacologica, et Toxicologica, November 1977 JARRATT et al., "The Effects of Intradermal Steriods on the Pituitary-Adrenal Axis and the Skin", The Journal of Investigative Dermatology, Vol. 62, No. 4, pp. 463-466, 1974 KIRKPATRICK, et al., "Local Anesthetic Efficacy of Methoxyflurane Microdroplets in Man", Vol. 67, No. 3A, Anesthesiology, September 1987 LEROY, et al., "Pharmacokinetics of Ceftazidime in Normal and Uremic Subjects", Antimicrobal Agents and Chemotherapy, Vol. 25, No. 3, pp. 638-642, May 1984 MCGUGAN, et al., "Adrenal Suppression from Intradermal Triamcinolone", The Journal of Investigative Dermatology, Vol. 40, pp. 271-272, Baltimore, MD., 1963 SCOTT, et al., "Toxicity of Interferon", Vol. 282, pp. 1345-1348, British Medical Journal, April 25, 1981 AX SUPERSAXO, et al., "Recombinant Human Interferon Alpha-2a: Delivery to Lymphoid Tissue by Selected Modes of Application", Pharmaceutical Research, Vol. 5, No. 8, pp. 472-476, August 1988 SUTHEREST, "Treatment of Pruritus Vulvae by Multiple Intradermal Injections of Alcohol. A Double-Blind Study, Vol. 86, pp. 371-373, British Journal of Obstetrics and Gynecology, May 1979 WARD, et al., "Pharmacokinetics of Methoxyflurane after its Intra-Dermal Injection as Lecithin-Coated Microdroplets", Vol. 9, pp. 1-12, Journal of Controlled Release, July 1989.			OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Methoxyflurane Microdropfets", Anestheiology, Vol. 63, No. 5. pp. 490-499, Nov. 1985 JAKOBSON, et al., "Variations in the Blood Concentration of 1, 1,2-Trichloroethane by Percutaneous Absorption and Other Routes of Administrion in the Guinea Pig", Vol. 41, No. 5, pp. 497-506, Acta Pharmacologica . et Toxicologica, November 1977 JARRATT, et al., "The Effects of Intradermal Steriods on the Pituitary-Adrenal Axis and the Skin", The Journal of Investigative Dermatology, Vol. 62, No. 4, pp. 463-466, 1974 KIRKPATRICK, et al., "Local Anesthetic Efficacy of Methoxyflurane Microdroplets in Man", Vol. 67, No. 3A, Anesthesiology, September 1987 LEROY, et al., "Pharmacokinetics of Ceftazidime in Normal and Uremic Subjects", Antimicrobal Agents and Chemotherapy, Vol. 25, No. 5, pp. 638-642, May 1984 MCGUGAN, et al., "Adrenal Suppression from Intradermal Triamcinolone", The Journal of Investigative Dermatology, Vol. 40, pp. 271-272, Baltimore, MD., 1963 SCOTT, et al., "Toxicity of Interferon", Vol. 282, pp. 1345-1348, British Medical Journal, April 25, 1981 AW SUPERSAXO, et al., "Recombinant Human Interferon Alpha-2a: Delivery to Lymphoid Tissue by Selected Modes of Application", Pharmaceutical Research, Vol. 5, No. 8, pp. 472-476, August 1988 SUTHEREST, "Treatment of Pruritus Vulvae by Multiple Intradermal Injections of Alcohol. A Double-Blind Study, Vol. 86, pp. 371-373, British Journal of Obstetrics and Gynecology, May 1979 WARD, et al., "Pruritus Vulvae: Treatment by Multiple Intradermal Alcohol Injections", Vol. 93, No. 2, pp. 201-204, British Journal of Dermatology, August 1975 WU, et al., "Pharmacokinetics of Methoxyflurane after its Intra-Dermal Injection as Lecithin-Coated Microdroplets", Vol. 9, pp. 1-12, Journal of Controlled Release, July 1989.			item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	
AR Absorption and Other Routes of Administration in the Guinea Pig", Vol. 41, No. 5, pp.497-506, Acta Pharmacologica . et Toxicologica, November 1977 JARRATT, et al., "The Effects of Intradermal Steriods on the Pituitary-Adrenal Axis and the Skin", The Journal of Investigative Dermatology, Vol. 62, No. 4, pp. 463-466, 1974 KIRKPATRICK, et al., "Local Anesthetic Efficacy of Methoxyflurane Microdroplets in Man", Vol. 67, No. 3A, Anesthesiology, September 1987 LEROY, et al., "Pharmacokinetics of Ceftazidime in Normal and Uremic Subjects", Antimicrobal Agents and Chemotherapy, Vol. 25, No. 5, pp. 638-642, May 1984 MCGUGAN, et al., "Adrenal Suppression from Intradermal Triamcinolone", The Journal of Investigative Dermatology, Vol. 40, pp. 271-272, Baltimore, MD., 1963 SCOTT, et al., "Toxicity of Interferon", Vol. 282, pp. 1345-1348, British Medical Journal, April 25, 1981 AW SUPERSAXO, et al., "Recombinant Human Interferon Alpha-2a: Delivery to Lymphoid Tissue by Selected Modes of Application", Pharmaceutical Research, Vol. 5, No. 8, pp. 472-476, August 1988 SUTHEREST, "Treatment of Pruritus Vulvae by Multiple Intradermal Injections of Alcohol. A Double-Blind Study, Vol. 86, pp. 371-373, British Journal of Obstetrics and Gynecology, May 1979 WARD, et al., "Pruritus Vulvae: Treatment by Multiple Intradermal Alcohol Injections", Vol. 93, No. 2, pp. 201-204, British Journal of Dermatology, August 1975 WU, et al., "Pharmacokinetics of Methoxyflurane after its Intra-Dermal Injection as Lecithin-Coated Microdroplets", Vol. 9, pp. 1-12, Journal of Controlled Release, July 1989.	B5	AQ	HAYNES, et al., "Ultra-long-duration Local Anesthesia Produced by Injection of Lecithin-coated Methoxyflurane Microdroplets", Anestheiology, Vol. 63, No. 5. pp. 490-499, Nov. 1985	
AS Journal of Investigative Dermatology, Vol. 62, No. 4, pp. 463-466, 1974 KIRKPATRICK, et al., "Local Anesthetic Efficacy of Methoxyflurane Microdroplets in Man", Vol. 67, No. 3A, Anesthesiology, September 1987 LEROY, et al., "Pharmacokinetics of Ceftazidime in Normal and Uremic Subjects", Antimicrobal Agents and Chemotherapy, Vol. 25, No. 5, pp. 638-642, May 1984 MCGUGAN, et al., "Adrenal Suppression from Intradermal Triamcinolone", The Journal of Investigative Dermatology, Vol. 40, pp. 271-272, Baltimore, MD., 1963 SCOTT, et al., "Toxicity of Interferon", Vol. 282, pp. 1345-1348, British Medical Journal, April 25, 1981 AW SUPERSAXO, et al., "Recombinant Human Interferon Alpha-2a: Delivery to Lymphoid Tissue by Selected Modes of Application", Pharmaceutical Research, Vol. 5, No. 8, pp. 472-476, August 1988 SUTHEREST, "Treatment of Pruritus Vulvae by Multiple Intradermal Injections of Alcohol. A Double-Blind Study, Vol. 86, pp. 371-373, British Journal of Obstetrics and Gynecology, May 1979 WARD, et al., "Pruritus Vulvae: Treatment by Multiple Intradermal Alcohol Injections", Vol. 93, No. 2, pp. 4201-204, British Journal of Dermatology, August 1975 WU, et al., "Pharmacokinetics of Methoxyflurane after its Intra-Dermal Injection as Lecithin-Coated Microdroplets", Vol. 9, pp. 1-12, Journal of Controlled Release, July 1989.	1	AR	Absorption and Other Routes of Administrtion in the Guinea Pig", Vol. 41, No. 5, pp. 497-506, Acta	
AT 3A, Anesthesiology, September 1987 LEROY, et al., "Pharmacokinetics of Ceftazidime in Normal and Uremic Subjects", Antimicrobal Agents and Chemotherapy, Vol. 25, No. 5, pp. 638-642, May 1984 AV MCGUGAN, et al., "Adrenal Suppression from Intradermal Triamcinolone", The Journal of Investigative Dermatology, Vol. 40, pp. 271-272, Baltimore, MD., 1963 SCOTT, et al., "Toxicity of Interferon", Vol. 282, pp. 1345-1348, British Medical Journal, April 25, 1981 AX SUPERSAXO, et al., "Recombinant Human Interferon Alpha-2a: Delivery to Lymphoid Tissue by Selected Modes of Application", Pharmaceutical Research, Vol. 5, No. 8, pp. 472-476, August 1988 SUTHEREST, "Treatment of Pruritus Vulvae by Multiple Intradermal Injections of Alcohol. A Double-Blind Study, Vol. 86, pp. 371-373, British Journal of Obstetrics and Gynecology, May 1979 WARD, et al., "Pruritus Vulvae: Treatment by Multiple Intradermal Alcohol Injections", Vol. 93, No. 2, pp. 201-204, British Journal of Dermatology, August 1975 WU, et al., "Pharmacokinetics of Methoxyflurane after its Intra-Dermal Injection as Lecithin-Coated Microdroplets", Vol. 9, pp. 1-12, Journal of Controlled Release, July 1989.		AS	JARRATT, et al., "The Effects of Intradermal Steriods on the Pituitary-Adrenal Axis and the Skin", The Journal of Investigative Dermatology, Vol. 62, No. 4, pp. 463-466, 1974	
AU AU AU AU ACGUGAN, et al., "Adrenal Suppression from Intradermal Triamcinolone", The Journal of Investigative Dermatology, Vol. 40, pp. 271-272, Baltimore, MD., 1963 SCOTT, et al., "Toxicity of Interferon", Vol. 282, pp. 1345-1348, British Medical Journal, April 25, 1981 AW SUPERSAXO, et al., "Recombinant Human Interferon Alpha-2a: Delivery to Lymphoid Tissue by Selected Modes of Application", Pharmaceutical Research, Vol. 5, No. 8, pp. 472-476, August 1988 SUTHEREST, "Treatment of Pruritus Vulvae by Multiple Intradermal Injections of Alcohol. A Double-Blind Study, Vol. 86, pp. 371-373, British Journal of Obstetrics and Gynecology, May 1979 WARD, et al., "Pruritus Vulvae: Treatment by Multiple Intradermal Alcohol Injections", Vol. 93, No. 2, pp. 201-204, British Journal of Dermatology, August 1975 WU, et al., "Pharmacokinetics of Methoxyflurane after its Intra-Dermal Injection as Lecithin-Coated Microdroplets", Vol. 9, pp. 1-12, Journal of Controlled Release, July 1989.		ĂT .	KIRKPATRICK, et al., "Local Anesthetic Efficacy of Methoxyflurane Microdroplets in Man", Vol. 67, No. 3A, Anesthesiology, September 1987	T
Dermatology, Vol. 40, pp. 271-272, Baltimore, MD., 1963 SCOTT, et al., "Toxicity of Interferon", Vol. 282, pp. 1345-1348, British Medical Journal, April 25, 1981 AW SUPERSAXO, et al., "Recombinant Human Interferon Alpha-2a: Delivery to Lymphoid Tissue by Selected Modes of Application", Pharmaceutical Research, Vol. 5, No. 8, pp. 472-476, August 1988 SUTHEREST, "Treatment of Pruritus Vulvae by Multiple Intradermal Injections of Alcohol. A Double-Blind Study, Vol. 86, pp. 371-373, British Journal of Obstetrics and Gynecology, May 1979 WARD, et al., "Pruritus Vulvae: Treatment by Multiple Intradermal Alcohol Injections", Vol. 93, No. 2, pp. 201-204, British Journal of Dermatology, August 1975 WU, et al., "Pharmacokinetics of Methoxyflurane after its Intra-Dermal Injection as Lecithin-Coated Microdroplets", Vol. 9, pp. 1-12, Journal of Controlled Release, July 1989.		ΑU	LEROY, et al., "Pharmacokinetics of Ceftazidime in Normal and Uremic Subjects", Antimicrobal Agents and Chemotherapy, Vol. 25, No. 5, pp. 638-642, May 1984	
AW SUPERSAXO, et al., "Recombinant Human Interferon Alpha-2a: Delivery to Lymphoid Tissue by Selected Modes of Application", Pharmaceutical Research, Vol. 5, No. 8, pp. 472-476, August 1988 SUTHEREST, "Treatment of Pruritus Vulvae by Multiple Intradermal Injections of Alcohol. A Double-Blind Study, Vol. 86, pp. 371-373, British Journal of Obstetrics and Gynecology, May 1979 WARD, et al., "Pruritus Vulvae: Treatment by Multiple Intradermal Alcohol Injections", Vol. 93, No. 2, pp. 201-204, British Journal of Dermatology, August 1975 WU, et al., "Pharmacokinetics of Methoxyflurane after its Intra-Dermal Injection as Lecithin-Coated Microdroplets", Vol. 9, pp. 1-12, Journal of Controlled Release, July 1989.		AV _.	MCGUGAN, et al., "Adrenal Suppression from Intradermal Triamcinolone", The Journal of Investigative Dermatology, Vol. 40, pp. 271-272, Baltimore, MD., 1963	
Modes of Application", Pharmaceutical Research, Vol. 5, No. 8, pp. 472-476, August 1988 SUTHEREST, "Treatment of Pruritus Vulvae by Multiple Intradermal Injections of Alcohol. A Double-Blind Study, Vol. 86, pp. 371-373, British Journal of Obstetrics and Gynecology, May 1979 WARD, et al., "Pruritus Vulvae: Treatment by Multiple Intradermal Alcohol Injections", Vol. 93, No. 2, pp. 201-204, British Journal of Dermatology, August 1975 WU, et al., "Pharmacokinetics of Methoxyflurane after its Intra-Dermal Injection as Lecithin-Coated Microdroplets", Vol. 9, pp. 1-12, Journal of Controlled Release, July 1989.		AW	SCOTT, et al., "Toxicity of Interferon", Vol. 282, pp. 1345-1348, British Medical Journal, April 25, 1981	T
Double-Blind Study, Vol. 86, pp. 371-373, British Journal of Obstetrics and Gynecology, May 1979 WARD, et al., "Pruritus Vulvae: Treatment by Multiple Intradermal Alcohol Injections", Vol. 93, No. 2, pp. 201-204, British Journal of Dermatology, August 1975 WU, et al., "Pharmacokinetics of Methoxyflurane after its Intra-Dermal Injection as Lecithin-Coated Microdroplets", Vol. 9, pp. 1-12, Journal of Controlled Release, July 1989.		AX	SUPERSAXO, et al., "Recombinant Human Interferon Alpha-2a: Delivery to Lymphoid Tissue by Selected Modes of Application", Pharmaceutical Research, Vol. 5, No. 8, pp. 472-476, August 1988	
WU, et al., "Pharmacokinetics of Methoxyflurane after its Intra-Dermal Injection as Lecithin-Coated Microdroplets", Vol. 9, pp. 1-12, Journal of Controlled Release, July 1989.		AY	SUTHEREST, "Treatment of Pruritus Vulvae by Multiple Intradermal Injections of Alcohol. A Double-Blind Study, Vol. 86, pp. 371-373, British Journal of Obstetrics and Gynecology, May 1979	
Microdroplets", Vol. 9, pp. 1-12, Journal of Controlled Release, July 1989.		AZ	WARD, et al., "Pruritus Vulvae: Treatment by Multiple Intradermal Alcohol Injections", Vol. 93, No. 2, pp. 201-204, British Journal of Dermatology, August 1975	
nec. 2.3 2002	$\overline{\bigvee}$	ВА	Microdroplets", Vol. 9, pp. 1-12, Journal of Controlled Release, July 1989.	
DEG 2 -			DEC 2 3 2002	
TECHNOLOGY CENTER			TECHNOLOGY CENTER	17

Examiner Signature BIMH TRAN Date Considered 07/05/03

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08B (10-01)
App of for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
4 of 4

Co	mplete if Known
Application Number	09/606,909
Filing Date	June 29, 2000
First Named Inventor	Pettis, et al.
Group Art Unit	3748
Examiner Name	Binh Q. Tran
Attorney Docket Number	P-4901

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1			
BT	ZAYNOUN, et al., "The Effect of Intracutaneous Glucocorticoids on Plasma Cortisol Levels", Vol. 88,			
-				
- .				
		RECEIVED		
ų -		DEC № 2002 TECHNOLOGY CENTER R3700		
•				
	!			

¹ Applicant's unique citation designation number (optional).
² Applicant is to place a check mark here if English language Translation is attached.



Examiner

Signature

Date

Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.